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Abstract
Introduction: Recent accumulating evidence indicates a crucial involvement of macrophage lineage in the 
pathogenesis of systemic sclerosis (SSc). To analyze the assembly of the monocyte/macrophage population, we 
evaluated the expression of CD163 and CD204 and various activated macrophage markers, in the inflammatory cells of 
the skin and in the peripheral blood mononuclear cells (PBMCs) derived from patients with SSc.
Methods: Skin biopsy specimens from 6 healthy controls and 10 SSc patients (7 limited cutaneous SSc and 3 diffuse 
cutaneous SSc) were analyzed by immunohistochemistry using monoclonal antibody against CD68 (pan-macrophage 
marker), CD163 and CD204. Surface and/or intracellular protein expression of CD14 (marker for monocyte lineage), 
CD163 and CD204 was analysed by flow cytometry in PBMCs from 16 healthy controls and 41 SSc patients (26 limited 
cutaneous SSc and 15 diffuse cutaneous SSc). Statistical analysis was carried out using Mann-Whitney U test for 
comparison of means.
Results: In the skin from SSc patients, the number of CD163+ cells or CD204+ cells between the collagen fibers was 
significantly larger than that in healthy controls. Flow cytometry showed that the population of CD14+ cells was 
significantly greater in PBMCs from SSc patients than that in healthy controls. Further analysis of CD14+ cells in SSc 
patients revealed higher expression of CD163 and the presence of two unique peaks in the CD204 histogram. 
Additionally, we found that the CD163+ cells belong to CD14brightCD204+ population.
Conclusions: This is the first report indicating CD163+ or CD204+ activated macrophages may be one of the potential 
fibrogenic regulators in the SSc skin. Furthermore, this study suggests a portion of PBMCs in SSc patients abnormally 
differentiates into CD14brightCD163+CD204+ subset. The subset specific to SSc may play an important role in the 
pathogenesis of this disease, as the source of CD163+ or CD204+ macrophages in the skin.
Introduction
Systemic sclerosis (SSc) is a multiorgan disease of
unknown etiology that is characterized by activation of
immune cells, production of autoantibodies and micro-
vascular injury, leading to fibrosis [1-6]. Histopathologi-
cal hallmarks of SSc are inflammatory infiltrates in early
disease stages and accumulation of extracellular matrix
proteins resulting in tissue fibrosis. Inflammatory infil-
trates are dominated by macrophages and T cells [7,8].
Monocytes, which leave from the bone marrow and
enter the circulation, are already mature cells (e.g., phago-
cytosing microbes and secreting cytokines), but these
functions are potentiated by further differentiation into
macrophages or dendritic cells in peripheral tissues [9].
Although the definition of the activated macrophages is
still controversial, heterogeneity of macrophages has
been discussed with regard to different responses to vari-
ous microenvironmental stimuli. Macrophages are classi-
cally activated toward M1 phenotype by microbial
products or interferon (IFN)-γ. M1 macrophages have
the IL-12high, IL-23high, IL-10low phenotype and produce
nitrogen intermediates and inflammatory cytokines such
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as IL-1β, TNF-α, and IL-6 to promote active inflamma-
tion [10,11]. In contrast, macrophages can be alterna-
tively activated toward M2 phenotype by stimulation
with IL-4 or IL-13 [10-12]. They are associated with a
high degree of vascularization and wound repair. Also,
these macrophages can play a role in certain fibrotic dis-
eases by producing transforming growth factor (TGF)-β
[13]. CD204 is considered as one of M2 markers [14,15],
whereas CD163 is also known as one of the markers for
activated macrophage; CD163 (haemoglobin scavenger
receptor) are reported to be up-regulated in active mac-
rophages under IL-10 stimulation [16].
On the other hand, several investigators have reported
the increased expression levels of IL-4, IL-13, and IL-10
in SSc serum [17-19]. They are cytokines that are respon-
sible for activation of macrophages as described above,
suggesting possible involvement of CD163+ or CD204+
activated macrophages in the pathogenesis of SSc. Mac-
rophages have been thought to be particularly activated
in patients with skin disease including SSc and are poten-
tially important sources for fibrosis-inducing cytokines,
such as TGF-β [7,8]. In addition, activated circulating
monocytes have also been reported in SSc patients, sup-
porting a possible involvement of these cells in the patho-
genesis of this disease [20,21]. However, no link between
CD163+ or CD204+ monocyte/macrophage lineage and
SSc has been established in the skin or in the peripheral
blood of SSc patients.
Therefore, to more fully explore the nature of altered
immune cell regulation in SSc patients, we showed the
distribution of cells with CD163 or CD204 in the skin
from healthy controls and SSc patients by immunohis-
tochemistry. In addition, we evaluated the population of
CD163+ or CD204+ cells in circulating monocytes of SSc
patients by flow cytometric analysis. We suggest that
CD163+  or CD204+ macrophages in the skin and the
CD14brightCD163+CD204+  monocyte subset in the
peripheral circulating blood are involved in the patho-
genesis of SSc.
Materials and methods
Patients and controls
Fifty-one SSc patients with a mean (± standard deviation
(SD)) age of 57.3 ± 14.1 years were from south Japan and
visited the outpatient clinic of the Department of Derma-
tology, Kumamoto University Hospital, Kumamoto,
Japan. Patients were grouped into either diffuse cutane-
ous SSc (dcSSc; n = 18) and limited cutaneous SSc (lcSSc;
n = 33) according to the classification system proposed by
LeRoy and colleagues [22]. Table 1 summarizes the
patient's clinical features. Skin biopsy specimens and
blood samples were obtained from patients after approval
by the ethical committee of the Kumamoto University
and gaining written informed consent. As healthy con-
trols, 22 disease-free volunteers (mean age; 44.1 ± 42.0
years) were enrolled in the study.
Antibodies for immunohistochemistry
The following antibodies were used: anti-human-CD68
(dilution 1: 300; mouse anti-human immunoglobulin (Ig)
G1, clone KP1; DakoCytomation, Carpinteria, CA, USA),
anti-human-CD163 (dilution 1:300; mouse anti-human
IgG1, clone 10D6; Novocastra, UK), and anti-human-
CD204 (mouse anti-human IgG1, clone SRA-E5, Trans
Genic, Kumamoto, Japan) [23,24].
Immunohistochemistry
Skin biopsy samples from the affected forearms of seven
lcSSc and three dcSSc patients were fixed in 10% neutral-
buffered formalin, embedded in paraffin, and sliced to a
size of 4 μm. After sections were deparaffinized in xylen
and rehydrated in a graded ethanol series, antigens were
retrieved by incubation with trypsin (Invitrogen, Carls-
bad, CA, USA) for 30 minutes for anti-human CD68 anti-
body. For staining with an anti-human CD163 or CD204
antibody, deparaffinized sections were retrieved by incu-
bation with target retrieval solution (Dako, Carpinteria,
CA, USA) or citrate buffer pH 6 for 5 minutes with a
microwave oven, respectively. Endogenous peroxide
activity was inhibited, after which sections were incu-
bated with 5% normal goat serum for 20 minutes and
then reacted with the monoclonal antibodies (anti-CD68,
CD163, or CD204 antibody) for six hours at 4°C. After
excess antibody was washed out with PBS, samples were
incubated with horseradish peroxidase-labelled goat anti-
mouse antibody (Nichirei, Tokyo, Japan) for 60 minutes.
The reaction was visualized using the diaminobenzidine
substrate system (Dojin, Kumamoto, Japan). Slides were
lightly counterstained with Mayer's hematoxylin, and
examined under a light microscope (OLYMPUS BX50,
Tokyo, Japan). Positive cells were counted three times,
and results were expressed as the average number of pos-
itive cells per 10,000 μm2 using ImageJ (National Insti-
tutes of Health, Bethesda, MD, USA).
Antibodies for flow cytometry
Monoclonal mouse anti-human CD14-phycoerythrin-
cyanin 5.1 (PC5) (Beckman Coulter Inc, Fullerton, CA,
USA) and anti-human CD163-phycoerythrin (PE)
(BioLegend Inc, San Diego, CA, USA) were used for sur-
face immunostaining. Anti-human CD204 (mouse anti-
human IgG1, clone SRA-E5) was purchased from Trans
Genic (Kumamoto, Japan) and purified using IgG Purifi-
cation Kit-A (Dojindo Laboratories, Kumamoto, Japan).
The purified CD204 antibody was sequentially conju-
gated with fluorescein isothiocyanate (FITC) using Fluo-
rescein Labelling Kit-NH2 (Dojindo Laboratories,
Kumamoto, Japan). The fluorescein/protein ratio wasHigashi-Kuwata et al. Arthritis Research & Therapy 2010, 12:R128
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determined by the absorbance of the protein solution at
208 nm and 500 nm. The CD204-FITC antibody was used
for both surface and intracellular staining. Appropriately
matched isotype control mAb to each antigen-specific
monoclonal antibody was used for control.
Isolation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were
obtained from heparinized venous blood, using gradient
centrifugation over Ficoll-Paque Plus (Amersham Biosci-
ences Corp, NJ, USA) according to the manufacturer's
protocol.
Flow cytometry
The cell number of isolated PBMCs (approximately 5 ×
105) were determined with Burker-turk line (Erma,
Tokyo, Japan) and blocked FcR with FcR Blocking
Reagent (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany) for 10 minutes at 4°C. Then, the cells (5 × 105 )
in each test tube was incubated for staining with isotype-
matched control antibody or relevant antibody (CD14,
CD163 or CD204) for 15 minutes at room temperature in
the dark. For intracellular staining, the cells were fixed
and permeabilized according to manufacturer's instruc-
tions using Intra Prep (Beckman Coulter Inc, Fullerton,
CA, USA). Then cells were washed once in PBS and fur-
ther incubated for intracellular staining with isotype-
matched control antibody or relevant antibody CD204
for 15 minutes at room temperature in the dark. Finally,
cells were washed three times, resuspended in 500 μl of
PBS containing 0.5% formaldehyde, and analyzed using a
Cytomics FC 500 (Beckman Coulter Inc, Fullerton, CA,
USA). The data was converted with FlowJo software
Table 1: Clinical features of the study subjects
Characteristics SSc (n = 51) Controls (n = 22)
lcSSc(n = 33) dcSSc (n = 18)
47/4
Sex (female/male) 32/1 15/3 18/4
57.3 (14.1)
Age (years), mean (SD) 59.3 (14.1) 55.1 (12) 44.1 (42.0)
Duration of disease 72.5 (1-240)
month, range (min-max) 74.5 (6-240) 54.5 (1-144)
Organ involvement (No) Esophagus 15 3
Heart 2 1
Kidney 0 0
Pulmonary hypertension 0 0
Pulmonary fibrosis 0 0
Sjögren syndrome 5 9
ANA Specificity (No) Anti-topo I 11 13
Anti-ACA 10 14
Anti-U1 RNP 3 3
Mean skin score (SD) 2.8 (3.4) 11.9 (9.4)
Steroid treatment 4 5
ANA, antinuclear antibodies; Anti-topo I, anti-topoisomerase I antibody; Anti-ACA, anti-centromere antibody; Anti-U1 RNP, anti-uridine 1 
ribonucleoprotein antibody; dcSSc, diffuse cutaneous systemic sclerosis; lcSSC, limited cutaneous systemic sclerosis; SD, standard deviation; 
SSC, systemic sclerosis.Higashi-Kuwata et al. Arthritis Research & Therapy 2010, 12:R128
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(Tree Star Inc, Ashland, OR, USA). Monocytes were
gated based on forward-sideward scatter profiles and
CD14 expression was used to verify whether the gated
cells were indeed monocytes.
Statistical analysis and clinical significance
Statistical analysis was carried out using Mann-Whitney
U test for comparison of means and Spearman's correla-
tion coefficient by rank for evaluating correlation of fac-
tors. Each protein expression level detected by flow
cytometry was represented by mean fluorescence inten-
sity (MFI). P values less than 0.05 were considered statis-
tically significant. All data were expressed as mean ± SD.
Results
First, we determined whether activated macrophages are
infiltrated in SSc skin. We found cells positive for CD68
(pan-macrophage marker), CD163 and CD204 were
increased not only in the perivascular regions but also
between thickened collagen bundles in the skin of SSc
patients (Figure 1). When the cell number in randomly
selected areas (per 10,000 μm2) was counted, the number
of CD68+, CD163+ or CD204+cells in the skin of SSc
patients was larger than that of healthy controls (5.3 ± 2.5
vs 2.2 ± 0.2, 4.0 ± 2.0 vs 1.3 ± 1.0 and 3.5 ± 1.6 vs 1.5 ± 0.5,
respectively; P < 0.05). In addition, to evaluate a contribu-
tion of macrophages to fibrosis, we further counted the
number of macrophages between collagen bundles,
excluding perivascular and periappendageal infiltrated
macrophages (Table 2). There was no difference in the
number of CD68+ cells between healthy controls and SSc
patients. However, the number of CD163+  cells and
CD204+ cells between the collagen fibers in the skin of
SSc patients were significantly greater than that of
healthy controls (3.8 ± 0.8 vs 1.2 ± 0.5 and 3.6 ± 0.6 vs 0.4
± 1.6, respectively; P  < 0.05, Table 2). The number of
CD68+, CD163+ or CD204+ cells in the randomly selected
areas or between collagen bundles of dcSSc skin did not
significantly differ from that of lcSSc skin. Thus, mac-
rophages between collagen fibers were activated to
express CD163+ and CD204+ in SSc skin, without chang-
ing the total number of macrophages.
To answer the question why the infiltration of activated
macrophage is increased in SSc skin, we then examined
PBMCs positive for CD14, which is widely accepted as a
useful marker of monocytes lineage, in SSc patients by
flow cytometry (Figure 2a). The population of CD14+
PBMCs was significantly greater in SSc patients than that
in healthy controls (19.6 ± 7.8% vs 11.5 ± 5.1%, P > 0.05;
Figure 2b). There was no significant difference between
lcSSc and dcSSc patients in the size of the population (P =
0.45). We confirmed that the CD14+ populations were
monocytes, by profiles of forward and side light scatter.
We next investigated expression levels of activated mac-
rophage markers (CD163 and CD204) in CD14+ PBMCs
of SSc patients and healthy controls by detecting MFI
(Figure 3a). We decided to stain both surface and intrac-
ellular CD204 because MFI of each surface or intracellu-
lar CD204 was not high enough to detect (data not
shown). Additionally, it has been also reported that
CD204 are mainly expressed in the endoplasmic reticu-
lum, nuclear envelope and Golgi apparatus of non-mono-
cyte lineage cells but moved to the cell surface and
endosomes of monocytes lineage-like cells [24]. MFI of
CD163 in CD14+ PMBCs of both lcSSc and dcSSc
patients was significantly greater than that of healthy
controls (Figures 3a and 3b), suggesting that monocytes
in SSc PMBCs already express activated macrophage
markers. On the other hand, MFI of CD204 in CD14+
PMBCs of lcSSc or dcSSc patients was not significantly
altered compared with those of healthy controls (Figure
3b). Of note, a histogram of surface and intracellular
CD204 showed two peaks; apparently weak and strong
positive populations (Figures 3a and 3c). Staining only
surface CD204 did not show such unique peaks in both
healthy controls and SSc patients (data not shown).
Indeed, the number of peaks in the CD204 histogram in
SSc patients was significantly larger than that in healthy
controls (Figure 3c).
To further characterize the feature of CD14+ PBMCs,
we performed three-color staining by CD14-PC-5,
CD163-PE, and CD204-FITC antibodies. Increased per-
centages of CD14+ cells in PBMCs from SSc patients
compared with that from healthy controls (Figure 2) was
confirmed by three-color staining (23.4% vs 8.1%, Figures
4a i and ii). Extended histogram representations clearly
revealed that there exists CD14dim and CD14bright subpop-
ulations in CD14+PMBCs and that the percentages of
CD14bright subpopulations was increased in SSc patients
compared with that from healthy controls (8.6% vs 0.8%;
Figures 4a iii and iv). Additionally, the dot plot represen-
tation of CD14 and CD163 staining demonstrated that
CD163+ cells belong to the CD14bright subpopulation in
both healthy controls and SSc patients (Figure 4b).
Extended dot plot representation also revealed the
CD14brightCD163+subpopulation co-expressed CD204
(Figure 4c). The population of CD14brightCD163+CD204+
subset in SSc PBMCs was significantly greater than that
in healthy controls (11.0 ± 9.0% vs 1.2 ± 0.1%, P < 0.05;
Figure 4d). Taken together, the presence of the
CD14brightCD163+CD204+ monocyte subset may be char-
acteristic in SSc PBMCs.
Discussion
Our study revealed three major findings. First, in the skin
from SSc patients, CD163 and CD204-positive activated
macrophages between the collagen fibers was signifi-Higashi-Kuwata et al. Arthritis Research & Therapy 2010, 12:R128
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cantly increased compared with that in healthy controls.
Second, in PBMCs from SSc patients, the population of
CD14+ cells was significantly greater than that of healthy
controls. Third, the expression levels of CD163 in SSc
CD14+ PBMCs was also significantly greater than that in
healthy controls and the CD163+  cells belong to the
CD14brightCD204+ population in SSc patients.
Expression of CD204 has been associated with an anti-
inflammatory M2 macrophage phenotype and believed to
be useful for distinguishing the M2 macrophages from
Table 2: Results of immunohistochemical staining
Number of positive cells (10000 μm2) SSc (n = 10) Controls (n = 6) P value
lcSSc (n = 7) dcSSc (n = 3)
3.2 ± 0.7 > 0.05
CD68 2.9 ± 1.0 3.2 ± 0.4 2.0 ± 0.2 > 0.05
3.8 ± 0.8 < 0.05*
CD163 4.0 ± 1.1 3.6 ± 0.5 1.2 ± 0.5 < 0.05*
3.6 ± 0.6 < 0.05*
CD204 3.4 ± 0.7 3.8 ± 0.4 1.4 ± 0.4 < 0.05*
Data are expressed as mean ± standard deviation; P < 0.05*.
The number of CD163+ and CD204+ cells between collagen fibers was significantly greater in SSc patients compared in healthy controls.
dcSSc, diffuse cutaneous systemic sclerosis; lcSSC, limited cutaneous systemic sclerosis; SSC, systemic sclerosis.
Figure 1 Immunoperoxidase staining of skin in SSc patients compared with that in healthy controls. Skin sections from (a to c) healthy con-
trols and (d to f) systemic sclerosis (SSc) patients were stained with anti-human-CD68, CD163 and CD204 antibody, respectively. A larger number of 
(d) CD68+ cells, (e) CD163+ cells and (f) CD204+ cells in SSc skin were distributed not only in the perivascular and periappendageal regions, but also 
between thickened collagen fibers compared with that in healthy control skin (a, b and c, respectively). Arrows indicate positively stained cells (brown); 
nuclei are counterstained with hematoxylin. Results are representative of 6 controls and 10 SSc patients. Bar = 100 μm.Higashi-Kuwata et al. Arthritis Research & Therapy 2010, 12:R128
http://arthritis-research.com/content/12/4/R128
Page 6 of 10
the pro-inflammatory M1 macrophages [14,15,25]. M2
macrophages are known to be increased in the early stage
of fibrosis. These cells release a number of proinflamma-
tory and fibrogenic mediators such as TGF-β [17]. We
p r e v i o u s l y  r e p o r t e d  a n  i n c r e a s e d  n u m b e r  o f  M 2  m a c -
rophages, CD204+ cells, in the skin from patients with
localized scleroderma [26]. This study suggests an impor-
tant role of M2 macrophage (i.e. secretion of TGF-β) in
the pathogenesis of SSc as well as localized scleroderma.
The exact mechanism or significance of CD163 expres-
sion on the active macrophages is unclear and the naming
of different macrophage subsets is still evolving, although
a recent article described that M2 macrophages can be
further subdivided into M2a (after exposure to IL-4 or IL-
13), M2b (forming immune complexes in combination
with IL-1β or lipopolysaccharide) or M2c (after exposure
to IL-10, TGF-β or glucocorticoids) [27]. Macrophages
positive for CD204 and CD163 may play a major role in
the formation of tissue fibrosis.
The population of CD14+ cells in circulating monocytes
in SSc patients has been reported [21]. Andrews and col-
leagues [21] did not find a significant difference in the
percentage of CD14+ PBMCs between SSc and healthy
controls using a fluorescence microscopy method,
whereas an increased population of CD14+ PBMCs in SSc
patients were found by flow cytometry in our study. This
discrepancy might be explained by the different method
used in the earlier study. Reduced or increased numbers
of CD14+ cells under pathological conditions have been
Figure 2 Increased number of CD14+ cells in (PBMCs) from SSc patients. Peripheral blood mononuclear cells (PBMCs) isolated from healthy con-
trols or systemic sclerosis (SSc) patients were analyzed by single-color flow cytometry for CD14 expression. Upper panel (a) shows the results of PBMCs 
from healthy controls (left), limited cutaneous systemic sclerosis (lcSSc) patients (middle), and diffuse cutaneous systemic sclerosis (dcSSc) patients 
(right). Values are the percentage of total PBMCs in each region. FL4, phycoerythrin-cyanin 5.1 fluorescence; SS, side scatter; #Cells = actual number 
of the cells. Data presented here are representative of 16 healthy controls and 41 SSc patients. Lower panel (b) depicts the summary of results, com-
paring percentages of CD14 positive cells in PBMCs (shown on the ordinate) from healthy controls and SSc patients. *P < 0.05 as compared with the 
value in cells from healthy controls.Higashi-Kuwata et al. Arthritis Research & Therapy 2010, 12:R128
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Figure 3 Expression level of CD163 and CD204 in CD14+ PBMCs. (a) Left panels (healthy controls) and middle panels (systemic sclerosis (SSc) pa-
tients) depict staining with each isotype-matched monoclonal antibody control (Iso) (unfilled graph) and antigen-specific monoclonal antibody indi-
cated (Test) (filled graph). Right panels depict staining with each monoclonal antibody in healthy controls (Test C) (fine line) versus SSc patients (Test 
SSc) (bold line). Data presented here are representative of 16 healthy controls and 15 (for CD163) or 41 (for CD204) SSc patients. (b) Comparison of 
expression level of CD163 and CD204 in CD14+ peripheral blood mononuclear cells (PBMCs) between healthy controls and SSc patients. Mean fluo-
rescence intensity (MFI) are shown on the ordinate. *P < 0.05 as compared with the value in cells from healthy controls. (c) The left panel shows the 
representative pattern of CD204 histogram. The number of peaks was counted as 1 in the (i) left panel, (ii) 1.5 in the middle panel and (iii) 2 in the 
right panel. The right panel shows increased number of peaks in CD204 histogram in SSc patients. The number of peaks is shown on the ordinate. * 
P < 0.05 as compared with the value in cells from healthy controls.Higashi-Kuwata et al. Arthritis Research & Therapy 2010, 12:R128
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reported [28,29]. Circulating CD14+ monocytes originate
from hematopoietic stem cells in the bone marrow. It has
been recently reported that the addition of IL-10 into
freshly isolated human monocytes results in a consider-
a b l e  i n c r e a s e  i n  C D 1 4  m R N A  in vitro [30]. Increased
numbers of CD14+ cells in our study may be partly inter-
preted as the direct result of increased serum IL-10 in SSc
patients, as described above [17,19]. Therefore we
hypothesized that increased numbers of circulating
CD14+ cell could be a source for the increased number of
CD68+ macrophages in the skin of SSc patients, which are
derived from migrated monocytes.
The expression levels of CD163 in PBMCs of SSc
patients were significantly higher than those of healthy
controls in our study. On the other hand, Andrews and
colleagues [21] also reported that monocytes in SSc
patients differed from those in normal controls and
appeared to have undergone advanced differentiation and
activation change (i.e. increased number of larger and
lightly stained esterase positive cells, decreased lectin
peanut agglutinin binding and decreased number of Leu
M2 surface antigen-positive cells). The significance of
CD163 expression on monocytes (not macrophages) is
also unknown. Higher CD163 expression in SSc CD14+
PBMCs in our study may indicate advanced differentia-
tion of monocytes into an active state. Considering that
CD163 expression on monocytes are modulated by pro-
anti-inflammatory mediators such as IL-10 [16,31], an
increased number of CD163+ cells in CD14+PBMCs in
our study may be interpreted as the direct result of
increased serum IL-10 in SSc patients [17-19]. Also,
another investigator recently reported that increased
gene expression levels of CD204 in PBMCs in patients
with acute coronary syndrome and concluded that the
CD204 levels could be a predictive marker for a reattack
of cardiovascular event [32]. Thus, our finding of the
unique pattern of CD204 histogram in SSc CD14+
PBMCs may indicate abnormal activation of monocytes.
As CD14brightCD163+CD204+ cells were not apparent in
PBMCs from healthy controls, the presence of this mono-
cyte subset may be highly specific to this disease. Taken
together, this subset of monocytes may play an important
r o l e  i n  S S c  a s  t h e  s o u r c e  o f  C D 1 6 3 + or CD204+ mac-
rophages in the skin.
Our results have some limitations. First, we could not
perform triple staining of CD68, CD163 and CD204 on
the same macrophage using serial skin sections. Second,
we could not find any correlation between the expression
of CD163 or CD204 in skin macrophages or the percent-
age of CD14brightCD163+CD204+  cells in PBMCs and
serum levels of cytokines (e.g. IL-10), the presence of
known disease-related factors (e.g. modified Rodnan's
skin score) or treatments as far as we determined (data
not shown). Further study will be needed in the future.
Figure 4 Gating process for detecting CD14brightCD163+CD204+ 
cells in CD14+hPBMCs. (a) Histogram representation of CD14+ cells in 
peripheral blood mononuclear cells (PBMCs) by three-color staining. 
Upper panels show the percentage of CD14+ cells in PBMCs from (i) 
healthy controls and (ii) systemic sclerosis (SSc) patients. Lower panels 
show enlarged histogram representation of the CD14+ population in 
PBMCs from (iii) healthy controls and (iv) SSc patients. Values over the 
horizontal bar are the percentage of CD14bright cells in CD14+ popula-
tion. (b) Dot plot representation of CD163+ cells in CD14+ population 
of PBMCs from healthy controls (left panel) and SSc patients (right pan-
el). CD163+ cells belonged to the CD14bright subpopulation, and the 
percentage of CD14bright CD163+ subpopulation in SSc patients was in-
creased compared with that in healthy controls. (c) Dot plot represen-
tation of CD163+ and CD204+ cells in CD14brightCD163+ population of 
PBMCs from healthy controls (left panel) and SSc patients (right panel). 
Further extended dot plot representation of CD14brightCD163+subpop-
ulation (an upper right quadrant of Figure 4b) revealed that these cells 
co-express CD204. Data presented in a to c are representative of 16 
healthy controls and 15 SSc patients. #Cells = actual number of the 
cells. (d) The graphic representation of quantitative result of 
CD14brightCD163+CD204+cells in PBMCs of SSc patients and healthy 
controls. Percentage of CD14brightCD163+CD204+ cells determined by 
flow cytometry is shown on the ordinate. P < 0.05.Higashi-Kuwata et al. Arthritis Research & Therapy 2010, 12:R128
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Conclusions
In the light of reported evidence, including present
results, we conclude that CD163+ or CD204+ activated
macrophages may be one of the potential fibrogenic regu-
lators in the SSc skin. Furthermore, this study suggests a
portion of PBMCs in SSc patients abnormally differenti-
ates into a CD14brightCD163+CD204+  subset. Further
studies to analyze the involvement of macrophages/
monocytes will provide a better understanding of the
pathogenesis of this disease.
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